The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.
Sarah Meskill, MD1; Laura B. Herpel, MD2,3; Michael J. Thorpy, MD4; Chad M. Ruoff, MD5; Diana Carino, PharmD, CSP, AAHIVP6; Erin Buysman, MS7; Michelle Vu, PharmD, MPH7; Brian Abaluck, MD8; Jennifer Gudeman, PharmD9,a
1Tricoastal Narcolepsy and Sleep Disorders Center, Sugar Land, TX, USA; 2Bogan Sleep Consultants, Columbia, SC, USA; 3Medical University of South Carolina, Charleston, SC, USA; 4Albert Einstein College of Medicine, New York, NY, USA; 5Mayo Clinic, Phoenix, AZ, USA; 6Optum Frontier Therapies, Las Vegas, NV, USA; 7Optum Life Sciences, Eden Prairie, MN, USA; 8Alkermes, Inc., Waltham, MA, USA*; 9Avadel Pharmaceuticals, Chesterfield, MO, USA; aAt the time of the study
